
A-Alpha Bio is a biotechnology company focused on accelerating therapeutic discovery by measuring, predicting, and engineering protein-protein interactions at scale. They leverage synthetic biology and machine learning through their proprietary platforms, AlphaSeq and AlphaBind. AlphaSeq is a high-throughput platform for quantitative characterization of protein-protein interactions, generating the world's largest repository of such data. AlphaBind uses this data to predict binding from protein sequence. A-Alpha Bio applies these technologies to internal therapeutic programs and partners with pharmaceutical companies to discover and develop novel therapeutics, including biologics and molecular glues.

A-Alpha Bio is a biotechnology company focused on accelerating therapeutic discovery by measuring, predicting, and engineering protein-protein interactions at scale. They leverage synthetic biology and machine learning through their proprietary platforms, AlphaSeq and AlphaBind. AlphaSeq is a high-throughput platform for quantitative characterization of protein-protein interactions, generating the world's largest repository of such data. AlphaBind uses this data to predict binding from protein sequence. A-Alpha Bio applies these technologies to internal therapeutic programs and partners with pharmaceutical companies to discover and develop novel therapeutics, including biologics and molecular glues.
Founded: 2017
Headquarters: Seattle, WA
Core tech: AlphaSeq (high-throughput PPI measurement) and AlphaBind (sequence-based binding prediction)
Industry: Biotechnology
Reported total funding: ~$64.05M (reported)
Protein–protein interaction measurement and prediction to support biologics discovery and engineering.
2017
Biotechnology
$2.8M
Seed to launch AlphaSeq
$20M
$22.4M
Recorded as a grant award
“Backed by a mix of venture investors and grant-making organizations, including Madrona Venture Group, Lux Capital, Perceptive Advisors, OS Fund, the Bill & Melinda Gates Foundation, and U.S. government grant support.”